Heron Therapeuti
$ 0.87
-2.44%
29 May - close price
- Market Cap 172,206,000 USD
- Current Price $ 0.87
- High / Low $ 0.89 / 0.85
- Stock P/E N/A
- Book Value 0.04
- EPS -0.18
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -24.09 %
- 52 Week High 2.30
- 52 Week Low 0.74
About
Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.
Analyst Target Price
$3.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-02-26 | 2025-11-04 | 2025-08-08 | 2025-05-06 | 2025-02-27 | 2024-11-12 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-14 | 2023-08-14 |
| Reported EPS | -0.04 | -0.02 | -0.1 | -0.02 | 0.0134 | 0.02 | -0.0317 | -0.06 | -0.02 | -0.07 | -0.17 | -0.35 |
| Estimated EPS | -0.02 | -0.015 | -0.01 | -0.01 | -0.01 | -0.025 | -0.03 | -0.04 | -0.09 | -0.16 | -0.29 | -0.23 |
| Surprise | -0.02 | -0.005 | -0.09 | -0.01 | 0.0234 | 0.045 | -0.0017 | -0.02 | 0.07 | 0.09 | 0.12 | -0.12 |
| Surprise Percentage | -100% | -33.3333% | -900% | -100% | 234% | 180% | -5.6667% | -50% | 77.7778% | 56.25% | 41.3793% | -52.1739% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HRTX
2026-05-27 02:09:09
This article provides the number of shareholders for Heron Therapeutics, Inc. (NASDAQ: HRTX). It appears to be a financial data page from TradingView, indicating the availability of shareholder information for the specified period.
2026-05-25 20:39:10
Heron Therapeutics Inc (HRTX) is deemed undervalued, with its current forward PS ratio of 0.84 significantly lower than its five-year average. The fair price for HRTX is estimated to be between $79.94 and $83.94, compared to its current price of $0.86, indicating it is undervalued by 98.93%. Despite a P/S ratio of 0.83, which is 99.72% above the industry average, and robust revenue growth of -10.78%, other metrics like P/B ratio and FCF yield show significant deviations from historical averages.
2026-05-25 00:10:10
Heron Therapeutics reaffirmed its 2026 revenue guidance of $550 million to $575 million, despite reporting a 13% decline in total net product sales for Q1 2026 to $27.9 million. The company's acute care segment showed significant growth, increasing 27% year-over-year to $23.6 million, largely driven by ZYNRELEF. However, oncology sales plummeted 67% to $4.3 million due to competition.
2026-05-19 07:08:00
H.C. Wainwright analyst Brandon Folkes reduced Heron Therapeutics, Inc.'s (HRTX) price target to $4 from $6, reiterating a Buy rating, following weaker-than-expected first-quarter performance and uncertainty regarding the Zynrelef product's growth. The company reported $34.7 million in Q1 2026 net revenue, with acute care revenue up 32% year-over-year, and reaffirmed full-year 2026 revenue guidance of $173–183 million. Despite product growth, the analyst emphasized the need for better revenue conversion and commercial momentum to sustain investor interest.
2026-05-15 17:39:11
The article reports that the price target for Heron Therapeutics (HRTX) has been reduced by 15.38%, bringing it down to $3.74. This adjustment reflects a significant change in the financial outlook for the company based on analyst expectations.
2026-05-15 15:09:32
Heron Therapeutics (HRTX) recently experienced a price target decrease of 15.38%, bringing it down to $3.74. This adjustment could reflect updated analyst expectations regarding the company's future performance or market conditions.
